Momenta Pharma (MNTA)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Momenta Pharma. The company’s shares closed last Monday at $18.94.
According to TipRanks.com, Archila is a 3-star analyst with an average return of 1.4% and a 47.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Momenta Pharma is a Strong Buy with an average price target of $28.33.
Iovance Biotherapeutics (IOVA)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics today and set a price target of $33.00. The company’s shares closed last Monday at $25.70.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 19.8% and a 67.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.25, which is a 27.3% upside from current levels. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA: